Total revenue rose 60% YoY to $6.4 million, while net loss per share improved 88% versus the prior-year quarter. Gross margin expanded to 40% as operating expenses stayed stable, supported by recent FDA clearance and the addition of new global distributors to drive ongoing commercial growth.
Total revenue rose 60% YoY to $6.4 million, while net loss per share improved 88% versus the prior-year quarter. Gross margin expanded to 40% as operating expenses stayed stable, supported by recent FDA clearance and the addition of new global distributors to drive ongoing commercial growth.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.45
